190 likes | 487 Views
. Background. In the SIRIUS trial, the Sirolimus-eluting Bx VELOCITY Stent (SES) showed significant benefit compared to the bare-metal Bx VELOCITY Stent control in short-term safety and efficacy, and this significant improvement has been sustained for all clinical endpoints (TLR, TVR, TVF, and MAC
E N D
1. Six-Year Outcomes After Sirolimus-eluting Stent Implantation (SIRIUS Study) Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J. Popma, Paul S. Teirstein, Jeffrey W. Moses, Huong P. Wang, Sidney A. Cohen, Donald E. Cutlip, for the SIRIUS Investigators
CRT 2009